TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
Clinical trial NCT07350070 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07350070
- Sponsor
- Tongji Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-31
- Primary completion
- 2027-06-30
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.